Skip to main content
Clinical Trials/NCT06176105
NCT06176105CompletedNot Applicable

Mortality After Transfusion of Ever-pregnant Donor Red Blood Cells

Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research1 site in 1 country101,000 target enrollmentStarted: October 1, 2019Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
101,000
Locations
1
Primary Endpoint
Mortality

Study Overview

Brief Summary

The MATER study is an observational cohort study on first ever transfusion recipients in six hospitals in the Netherlands, with information collected on both donor and patient characteristics. We aim to further specify which combination of characteristics of both donors and patients determine the increased risk of mortality after blood transfusions.

Detailed Description

Background In 2011, a link between donor sex and death of transfusion recipients was observed in red blood cell transfusions (Middelburg et al., Vox Sanquinis, 2011). This was further investigated by Caram-Deelder et al., who showed the transfusion of red blood cells from ever-pregnant donors was associated with higher mortality in young men (with age up to 50 years) (Caram-Deelder et al., JAMA, 2017). However, the biological mechanisms explaining this association remained unclear. More data is needed to be able to specify which combination of characteristics of both donors and patients determines this increased risk of mortality after red blood cell transfusions. Therefore, the MATER study was initiated: 'Mortality After Transfusion of Ever-pregnant donor Red blood cells'. Here, we aim to validate previous research on the association between donor pregnancy history and transfusion recipient mortality.

Rationale Red blood cells constitute the biggest part of the blood supply. They are currently transfused without consideration of the sex of the blood donor and the recipient. Recent evidence shows such a policy to be associated with increased mortality in male recipients of red blood cells from female donors with a history of pregnancy. This project aims to find clues for the biological mechanism behind this association. This knowledge will allow for more personalized future transfusion strategies that will minimize both side effects and associated mortality of recipients of red blood cell transfusions.

Methodology First-ever transfusion recipients in the Netherlands between 2005 and 2018 which were performed in the hospitals participating in the R-FACT study will be included in this study. All blood donations and the corresponding donors linked to these recipients will be included in this study. Cox regression analysis will be used to assess the effect of donor pregnancy on transfusion recipient mortality. This analysis method allows modelling the relation between exposure (donor pregnancy history), outcome (mortality), and confounders (e.g. total number of transfusions, year of transfusion, ABO and Rh blood type, sex of the patient, and hospital) taking into account that exposure and confounders vary over time. Pregnancy history will be investigated as number of pregnancies, time since last pregnancy, different partners and type of pregnancy (i.e. boy versus girl pregnancies, outcome of pregnancy). The hazard ratio will be presented for exposure to blood products with different characteristics, stratified by patient age, sex and (if possible) transfusion indication. Effect modification by storage time will also be investigated.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •have received a first transfusion between 20-03-2004 and 31-12-2018 in one of the hospitals participating in the R-FACT study OR
  • •have donated blood for a blood product which was used in one of the hospitals participating in the R-FACT study between 20-03-2004 and 31-12-2018

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Mortality

Time Frame: 2015-2018

In total, this cohort contains data on over 100,000 first-ever transfusion recipients and their received transfusions from six hospitals in the Netherlands, with information collected on both donor and patient characteristics.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Study of Transfusion-Transmitted InfectionsTransfusion-Transmitted InfectionsViral DiseaseBlood Donation
NCT00023023National Institutes of Health Clinical Center (CC)1,771
Unknown
Not Applicable
A prospective cohort study of blood transfusion-dependent chronic anemia in AkitaChronic anemia dependent on red cell transfusion
JPRN-UMIN000001908Akita University School of Medicine, Department of Medicine, Division of Hematology, Nephrology and Rheumatology100
Active, not recruiting
Not Applicable
Prospective Study on Feto-maternal outcoMe In aNemIc womEnBleedingEmbolism, Thrombus TransfusionTransfusion-dependent AnemiaPregnancy AnemiaPregnancy BleedingPlacenta DiseasesAnemia
NCT05739097Casa Sollievo della Sofferenza IRCCS2,000
Completed
Not Applicable
Transfusion Requirements and Mortality during Extracorporeal Membrane OxygenatioECMO is indicated in case of potentially reversible cardio(respiratory) failure refractory to conventional therapies. It can be divided in two main groups: the respiratory indications (e.g. acute respiratory distress syndrome), for which veno-venous ECMO is indicatedand isolated cardiac or combined cardiorespiratory failure (e.g. acute myocardial infarction), for which veno-arterial ECMO is indicated. It is a vulnerable population in the ICU, for which ECMO often functions as a last resort” therapy.
NL-OMON24666/A600
Unknown
Not Applicable
Impact of Transfusional Practice on the Morbidity and Mortality of Patients in Intensive Care UnitTransfusion Related Complication
NCT03934112Centre Hospitalier Universitaire de Besancon150,000